从定价来看，双靶点的玛仕度肽的定价直接对标诺和诺德的明星减重药司美格鲁肽（商品名：诺和盈），但仍低于同为双靶点机制的礼来 减重药替尔泊肽（商品名：穆峰达）。 "现在患者已经有三个GLP-1减重药可以选择了，以后的选择还会越来越多，这个领域的趋势必然是越来越卷。"李小英对第一财经记者表 示。 从定价来看，双靶点的玛仕度肽的定价直接对标诺和诺德的明星减重药司美格鲁肽，但仍低于同为双靶点机制的礼来减重药替尔泊肽。 日前，备受关注的国产GLP-1减重药玛仕度肽（商品名：信尔美）在上海开出全市公立医院和私立医院的首张处方，为患者提供了进口减 重药之外的新选择。 第一财经记者在复旦大学附属中山医院内分泌科采访时了解到，该院内分泌科主任李小英教授为一位超重合并轻度脂肪肝的27岁男性患者 开具了玛仕度肽，患者目前仍需要凭处方在药房购买该药物。 针对患者如何在目前已有的三种减重药当中做选择，李小英解释道，主要看患者的合并症。"比如合并脂肪肝的，现在研究发现玛仕度肽对 脂肪肝治疗有一定效果，我们发现临床上肥胖患者约60%都有脂肪肝。"他说道。 纪立农此前也对第一财经记者表示，不能寄希望于用减重药解决所有的肥胖问题。"我们要强调， ...

Core Viewpoint - The approval of "Marsutide" by Innovent Biologics and Eli Lilly for weight management marks a significant entry into the competitive GLP-1 market, dominated by Novo Nordisk and Eli Lilly, but faces substantial commercialization challenges ahead [1][2]. Group 1: Product Approval and Market Position - "Marsutide" is the first GCG/GLP-1 dual receptor agonist approved for weight management, targeting adults with a BMI of 28 kg/m² or higher, or 24 kg/m² with weight-related comorbidities [1]. - The global GLP-1 market is currently led by Novo Nordisk's semaglutide with projected sales of approximately $29.296 billion in 2024 and Eli Lilly's tirzepatide with revenues of $16.46 billion, creating a formidable market barrier for new entrants [2]. Group 2: Clinical Efficacy - Clinical trial data from the GLORY-1 Phase III study shows that the 4 mg and 6 mg doses of "Marsutide" resulted in average weight reductions of 11.00% and 14.01%, respectively, significantly outperforming the placebo group [3]. - "Marsutide" is undergoing head-to-head clinical trials against tirzepatide to validate its efficacy further, with the potential to become the leading weight management drug if successful [3]. Group 3: Commercialization Challenges - The strategy of launching "Marsutide" directly for weight management, rather than a gradual approach starting with diabetes treatment, presents significant commercialization hurdles due to limited access in public hospitals [4][5]. - The reliance on specialized obesity clinics for prescriptions poses a natural bottleneck for "Marsutide" in the Chinese healthcare system, limiting its market penetration [4]. Group 4: Marketing Strategy - Innovent Biologics is focusing on differentiated marketing strategies, leveraging existing brand influence in public hospitals and rapidly establishing weight management clinics [6]. - The pricing strategy for "Marsutide" is set above semaglutide but below tirzepatide, aiming to compete on efficacy and cost-effectiveness [6]. Group 5: Future Industry Trends - The GLP-1 market is shifting from a focus on "weight loss efficiency" to "weight loss quality," with international competitors developing products that not only promote weight loss but also enhance muscle gain [7][8]. - Innovent is pursuing additional clinical studies for "Marsutide" targeting adolescent obesity and other metabolic conditions, but these efforts are long-term and carry significant uncertainty [8]. Group 6: Financial Preparations - Innovent has raised $550 million through a new share placement to fund international multi-center trials and support the initial commercialization of "Marsutide" [9]. - The company is preparing for a competitive landscape as patents for leading GLP-1 drugs expire, potentially leading to an influx of generic competitors by 2027 [9].

2025.07. 06 本文字数：5463，阅读时长大约9分钟 作者 | 第一财经 钱童心 伴随着国产GLP-1减重药玛仕度肽（商品名：信尔美）的商业化落地，国内减重药市场格局迎来了 新的变化。全球两大减重药巨头诺和诺德与礼来在中国市场将面临更激烈的竞争环境，减重药未来价 格是否会出现松动也引发关注。 减重药市场迎来"新玩家" 7月3日，信达生物的GLP-1减重创新药玛仕度肽"首方"落地。北京大学人民医院分泌科主任医师纪 立农教授为一名超重合并脂肪肝的患者开出全国首张处方，标志着玛仕度肽正式进入国内公立医院。 这距离该药物获批仅一周之隔。下周起，该药物将陆续进入全国各大公立医院。 相比之下，诺和诺德的司美格鲁肽减重适应症（商品名：诺和盈）从获批到正式商业化开出公立医 院"首方"历时近5个月；礼来的替尔泊肽减重适应症从获批到上市也经历了近半年时间。 "国内厂商没有产能供应限制的问题。"一位业内人士对第一财经记者。另据记者了解，直到目前为 止，司美格鲁肽与替尔泊肽均尚未在国内实现本土化生产。 在信达生物此前召开的产品上市发布会上，信达生物首席财务官由飞表示，对于玛仕度肽的市场潜 力，公司非常有信心。在渠道拓展方面 ...

Group 1: Market Dynamics - The domestic GLP-1 weight loss drug market is experiencing changes with the commercialization of the domestic drug Masitide (brand name: Xin'ermei), which may lead to price reductions as more products enter the market and potentially get included in medical insurance [1][6] - The entry of domestic manufacturers like Shinda Biologics is expected to intensify competition against global giants Novo Nordisk and Eli Lilly, which have dominated the market [3][7] - The global GLP-1 drug market is projected to exceed $60 billion by 2025, with China's market expected to reach 20 billion RMB, growing at an annual rate of over 28% [4] Group 2: Product Launch and Competition - Masitide has officially entered public hospitals in China, marking a significant milestone for domestic GLP-1 drugs, with expectations of capturing a substantial market share [3][5] - The pricing strategy for Masitide will reflect its clinical value while considering the pricing of existing products and the payment capabilities of domestic patients [5][6] - Novo Nordisk and Eli Lilly are actively expanding their product lines and indications to maintain their competitive edge, with Novo Nordisk's semaglutide showing a 20% reduction in major adverse cardiovascular events [7][9] Group 3: Consumer Behavior and Market Potential - The strong consumer demand for weight loss drugs is evident, with many patients advised to use GLP-1 drugs long-term for weight management and blood sugar control [16][18] - Despite the high prices of GLP-1 drugs in China, there is significant unmet demand, as many patients are unaware of the availability of domestic options [6][19] - The potential for commercial insurance to cover GLP-1 drugs is increasing, which may enhance patient affordability and access [18] Group 4: Future Developments - There is a growing interest in oral GLP-1 drugs, which could address the market demand for easier administration compared to injectable forms [11][12] - Companies are also focusing on developing new drugs that can help maintain muscle mass while promoting fat loss, addressing a significant side effect of current GLP-1 treatments [13][15] - The obesity epidemic in China presents a vast market opportunity, with projections indicating that by 2030, two-thirds of the adult population may be overweight or obese [19]

此外，就在7月1日，翰宇药业发布今年半年利润的业绩预告称：2025年上半年，公司预计实现归母净利 润1.42亿-1.62亿元，同比增幅高达1470%-1664%；扣非净利润1.22亿元-1.42亿元，同比增长 304.27%-337.76%。值得注意的是，翰宇药业能做到这一步实在不容易，公司曾陷于扣非净利润亏损长 达7年之久，这还是首次实现扭亏为盈。翰宇药业将最大功臣归于其"减重神药"利拉鲁肽注射液仿制药 的出海成功以及原料药的国际收入和成本控制等。去年12月，其仿制的利拉鲁肽注射液在美国上市，并 和美国合作伙伴Hikma采取"低出货价+高利润分成的BD"模式。 外资药企进军新赛道 与此同时，外资药企也并没有"坐等"后来者赶超，而是在不断开拓进军新赛道。就在2025年6月30日， 礼来宣布穆峰达®（替尔泊肽注射液）获得中国国家药品监督管理局批准，成为首个且目前唯一用于治 疗成人肥胖患者的中度至重度阻塞性睡眠呼吸暂停（OSA）的处方药。替尔泊肽可改善中度至重度阻塞 性睡眠呼吸暂停肥胖成人患者的睡眠障碍。该适应症的使用需在控制饮食和增加运动基础上进行。 据悉，除了改善睡眠呼吸暂停症状外，接受替尔泊肽治疗的成人患者 ...

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 你有没有注意到，身边"胖起来"的人越来越常见？ 其实，国际上衡量胖瘦最常用的标准并不是单纯的体重，而是BMI（身体质量指数）。BMI的计算方法是：体重（公斤）除以身高（米）的平 方。BMI在18.5到23.9之间属于正常，超过24为超重，28以上即为肥胖，30及以上则被视为中重度肥胖。 2016年，《柳叶刀》杂志发布的数据显示，全球肥胖人数首次超过了体重偏轻的人群，而中国的肥胖总人数已跃居全球第一，超过美国。 最新的《中国居民膳食营养素参考摄入量》也显示，我国居民超重和肥胖的比例持续上升，成年人肥胖率已超过50%，儿童和青少年超重及肥 胖率也接近20%。 伴随着"胖人"队伍的不断壮大，各种减肥方法层出不穷，在社交平台上不断刷屏。 比如，男演员尹正因分享自己的减脂餐单，意外成为小红书上的热门人物；沈腾公开的"16+8减肥法"（每天连续禁食16小时，其余8小时进 食），更被不少年轻人奉为减肥宝典。 但是，无论是明星还是普通人，减肥这条路都不轻松。 尹正虽然 ...

Core Viewpoint - JD Health is establishing a comprehensive and multi-layered service system in the weight loss sector, integrating medical resources, innovative drug introduction, health management services, AI technology, and a strong supply chain to provide a full-chain solution for scientific weight loss [1][5]. Group 1: Innovative Drug Introduction - JD Health collaborates with renowned domestic and international pharmaceutical companies to introduce innovative weight loss drugs, ensuring users have access to cutting-edge weight loss solutions [2]. - The recently launched drug, "Xin Er Mei" (Magsduet injection), is the world's first approved GCG/GLP-1 dual receptor agonist for weight loss, which improves both weight and metabolic indicators while effectively reducing visceral fat [2]. - The drug features a painless injection technology that enhances the user experience, allowing users to easily connect with offline medical institutions through the JD APP [2]. Group 2: Comprehensive Service System - JD Health has initiated the "Scientific Weight Management Ecological Co-construction Initiative" to build a full-chain service system encompassing prevention, diagnosis, and management [4]. - The JD Internet Hospital collaborates with top doctors to offer personalized weight loss plans, having served over 10,000 users with a satisfaction rate of 99% [4]. - The "Simai Companion Six-in-One Test" project provides convenient home testing services for users of GLP-1 drugs, ensuring safe and effective medication [4]. Group 3: AI and Technology Integration - JD Health leverages its self-developed "JD Medical Qianxun" model to create AI tools such as AI doctors, AI pharmacists, and AI nutritionists, providing 24/7 online consultation services [4]. - These AI tools generate personalized dietary and exercise recommendations based on users' health conditions and weight loss goals, while also monitoring progress and adjusting plans in real-time [4]. Group 4: Supply Chain and Market Position - JD Health demonstrates strong supply chain advantages and service capabilities in the weight loss sector, responding to the "Weight Management Year" policy and promoting the adoption of scientific weight loss concepts [5]. - The company aims to provide efficient, inclusive, and professional health management solutions for an increasing number of users needing weight loss support [5].

整理 | GLP1减重宝典内容团队 一句"国家喊你减重"，体重管理年拉开全民甩脂的序幕。越来越多人意识到，超重与肥胖不只是审美问题，而是关乎亿万人健康的公共卫生课 题。 你真的需要减重吗？怎么设定减重目标更科学？ 7月4日，在阿里健康科学减重标准发布会上，北京大学人民医院内分泌科主任、北京大学糖尿病中心主任纪立农教授与阿里健康联合发布"科学 减重标准"，希望通过规范的营养管理、运动干预、药物治疗，帮助超重与肥胖人群开启科学减重之旅。 （北京大学人民医院内分泌科主任纪立农教授发言） "在体重管理过程中，信息不对称、方法不科学是困扰用户的最核心问题。基于服务亿万消费者的用户洞察，和长期深耕慢病管理的专业积累， 阿里健康将为用户提供专业、科学的减重指导和陪伴式服务。"阿里健康执行董事兼首席执行官沈涤凡表示，即日起，阿里健康将联合礼来、信 达、银诺等中外药企推出科学减重计划，为用户提供"一对一专属医生答疑、药师服务"等一揽子计划。 （阿里健康执行董事兼首席执行官沈涤凡发言） （阿里健康与众安保险签约） （阿里健康科学减重标准正式发布） 根据国家卫健委发布的《成人肥胖食养指南（2024年版）》，我国18岁及以上居民超重 ...

第一财经记者了解到，信达生物GLP-1类减重创新药玛仕度肽已于7月3日在北京大学人民医院开出 全国首张处方。北京大学人民医院纪立农教授为一位超重并伴有脂肪肝的患者开具处方，标志着该药 物在全国正式进入商业化。 ...

Core Viewpoint - The approval and prescription of Marsutide (brand name: Xinermai), the world's first dual-target weight loss drug combining glucagon (GCG) and glucagon-like peptide-1 (GLP-1), marks a significant advancement in obesity treatment in China [1][2]. Group 1: Product Overview - Marsutide was approved for market release on June 27, 2023, and is designed for long-term weight management in adults [1]. - The drug operates through a dual mechanism of action: it suppresses appetite via GLP-1 receptors and promotes fat burning through GCGR, addressing complex metabolic issues such as visceral fat accumulation and insulin resistance [2]. Group 2: Market Context - The obesity rate in China is rising, particularly among the young and middle-aged population, prompting increased public awareness and demand for professional weight management solutions [1]. - Patients seeking weight loss solutions often have previously attempted various methods without success, indicating a potential market for effective pharmaceutical interventions [2]. Group 3: Clinical Evidence - In clinical studies (GLORY-1), patients treated with Marsutide showed significant reductions in triglycerides and low-density lipoprotein cholesterol, with liver fat content decreasing by an average of 80% in those with fatty liver disease [1][2].